Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site

被引：0
|
作者：
Uematsu, Shinya [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Div Thorac Med Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz338.080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO2 - 16 -
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [1] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [2] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [3] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [4] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [5] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [6] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [7] SAFETY AND EFFICACY OF OSIMERTINIB AS A THERAPY IN PATIENTS WITH EGFR T790M POSITIVE NON SMALL CELL LUNG CANCER PATIENTS: A SYSTEMATIC REVIEW
    Gadi, H. R.
    Ganta, M. R.
    Voleti, V. B.
    Rayavarapu, J. E.
    Thatavarti, R.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A418 - A418
  • [8] ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)
    Cheema, P. K.
    Chen, Y-M.
    de Marinis, F.
    Freitas, H. C.
    Kim, S-W.
    Milner, A.
    Provencio, M.
    Rigas, J.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [10] EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
    Sonoda, Tomoaki
    Nishikawa, Shingo
    Sakakibara, Rie
    Saiki, Masafumi
    Ariyasu, Ryo
    Koyama, Junji
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Ohyanagi, Fumiyoshi
    Ninomiya, Hironori
    Ishikawa, Yuichi
    Nishio, Makoto
    [J]. RESPIRATORY MEDICINE CASE REPORTS, 2018, 24 : 19 - 21
12345